Literature DB >> 8971007

Elimination of hepatitis C virus RNA in infected human hepatocytes by adenovirus-mediated expression of ribozymes.

A Lieber1, C Y He, S J Polyak, D R Gretch, D Barr, M A Kay.   

Abstract

Hepatitis C virus (HCV), a positive-strand RNA virus, is the major infectious agent responsible for causing chronic hepatitis. Currently, there is no vaccine for HCV infection, and the only therapy for chronic hepatitis C is largely ineffective. To investigate new genetic approaches to the management of HCV infection, six hammerhead ribozymes directed against a conserved region of the plus strand and minus strand of the HCV genome were isolated from a ribozyme library, characterized, and expressed from recombinant adenovirus vectors. The expressed ribozymes individually or in combination were efficient at reducing or eliminating the respective plus- or minus-strand HCV RNAs expressed in cultured cells and from primary human hepatocytes obtained from chronic HCV-infected patients. This study demonstrates the potential utility of ribozyme therapy as a strategy for the treatment of hepatitis C virus infection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8971007      PMCID: PMC190975     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  Adenovirus-mediated transfer of the amphotropic retrovirus receptor cDNA increases retroviral transduction in cultured cells.

Authors:  A Lieber; M J Vrancken Peeters; M A Kay
Journal:  Hum Gene Ther       Date:  1995-01       Impact factor: 5.695

2.  Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides.

Authors:  M Alt; R Renz; P H Hofschneider; G Paumgartner; W H Caselmann
Journal:  Hepatology       Date:  1995-09       Impact factor: 17.425

Review 3.  Antiviral and anticancer ribozymes.

Authors:  E Poeschla; F Wong-Staal
Journal:  Curr Opin Oncol       Date:  1994-11       Impact factor: 3.645

Review 4.  Development of ribozymes for gene therapy.

Authors:  S M Sullivan
Journal:  J Invest Dermatol       Date:  1994-11       Impact factor: 8.551

5.  Therapeutic serum concentrations of human alpha-1-antitrypsin after adenoviral-mediated gene transfer into mouse hepatocytes.

Authors:  M A Kay; F Graham; F Leland; S L Woo
Journal:  Hepatology       Date:  1995-03       Impact factor: 17.425

6.  Specific inhibition of hepatitis C virus expression by antisense oligodeoxynucleotides. In vitro model for selection of target sequence.

Authors:  T Wakita; J R Wands
Journal:  J Biol Chem       Date:  1994-05-13       Impact factor: 5.157

7.  Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant.

Authors:  A Weiner; A L Erickson; J Kansopon; K Crawford; E Muchmore; A L Hughes; M Houghton; C M Walker
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

8.  Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C.

Authors:  M Martinot-Peignoux; P Marcellin; M Pouteau; C Castelnau; N Boyer; M Poliquin; C Degott; I Descombes; V Le Breton; V Milotova
Journal:  Hepatology       Date:  1995-10       Impact factor: 17.425

9.  Persistent hepatitis C virus infection after liver transplantation: clinical and virological features.

Authors:  D R Gretch; C E Bacchi; L Corey; C dela Rosa; R R Lesniewski; K Kowdley; A Gown; I Frank; J D Perkins; R L Carithers
Journal:  Hepatology       Date:  1995-07       Impact factor: 17.425

Review 10.  Variability of hepatitis C virus.

Authors:  P Simmonds
Journal:  Hepatology       Date:  1995-02       Impact factor: 17.425

View more
  19 in total

Review 1.  Perspectives for the treatment of infections with Flaviviridae.

Authors:  P Leyssen; E De Clercq; J Neyts
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

2.  Growth arrest of Epstein-Barr virus immortalized B lymphocytes by adenovirus-delivered ribozymes.

Authors:  S Huang; D Stupack; P Mathias; Y Wang; G Nemerow
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

3.  Characterization of a monoclonal antibody and its single-chain antibody fragment recognizing the nucleoside Triphosphatase/Helicase domain of the hepatitis C virus nonstructural 3 protein.

Authors:  Z X Zhang; U Lazdina; M Chen; D L Peterson; M Sällberg
Journal:  Clin Diagn Lab Immunol       Date:  2000-01

4.  Identification of eIF2Bgamma and eIF2gamma as cofactors of hepatitis C virus internal ribosome entry site-mediated translation using a functional genomics approach.

Authors:  M Kruger; C Beger; Q X Li; P J Welch; R Tritz; M Leavitt; J R Barber; F Wong-Staal
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

5.  Design and analysis of hammerhead ribozyme activity against an artificial gene target.

Authors:  James R Carter; Pruksa Nawtaisong; Velmurugan Balaraman; Malcolm J Fraser
Journal:  Methods Mol Biol       Date:  2014

6.  A prenylation inhibitor prevents production of infectious hepatitis delta virus particles.

Authors:  Bruno B Bordier; Patricia L Marion; Kazuo Ohashi; Mark A Kay; Harry B Greenberg; John L Casey; Jeffrey S Glenn
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

7.  Secondary structure and hybridization accessibility of hepatitis C virus 3'-terminal sequences.

Authors:  Robert M Smith; Cherie M Walton; Catherine H Wu; George Y Wu
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  Selective killing of cancer cells by Ashwagandha leaf extract and its component Withanone involves ROS signaling.

Authors:  Nashi Widodo; Didik Priyandoko; Navjot Shah; Renu Wadhwa; Sunil C Kaul
Journal:  PLoS One       Date:  2010-10-21       Impact factor: 3.240

9.  Development of lead hammerhead ribozyme candidates against human rod opsin mRNA for retinal degeneration therapy.

Authors:  Heba E Abdelmaksoud; Edwin H Yau; Michael Zuker; Jack M Sullivan
Journal:  Exp Eye Res       Date:  2008-12-06       Impact factor: 3.467

10.  Inhibition of hepatitis C virus nonstructural protein, helicase activity, and viral replication by a recombinant human antibody clone.

Authors:  Ramesh Prabhu; Nutan Khalap; Roberto Burioni; Massimo Clementi; Robert F Garry; Srikanta Dash
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.